evipedia.ai
← Back

Modafinil for Health & Longevity

Evidence Review created on 10/25/2026 using AI4L / Opus 5.5

Also known as: Provigil, Modiodal, Modasomil, Vigil, Alertec, Modalert, Modvigil, CRL-40476

Motivation

Modafinil is a prescription medication that promotes wakefulness, first sold in France as Modiodal and best known as Provigil. It works mainly by slowing the brain’s clearance of dopamine, though how far it differs from older stimulants is still debated. Beyond its approved medical uses, it has become one of the most widely discussed “smart drugs” among people who want clearer focus, longer productive days and an answer to jet lag or lost sleep.

The drug was developed in France to treat disorders of excessive daytime sleepiness. Military researchers later studied it as a way to keep personnel functional through long operations without sleep, and its reputation spread to students and professionals who use it without a medical need. That spread raised a practical question for health-focused adults: what a wakefulness medication offers people who are not ill, and at what cost.

This review examines the human evidence on modafinil’s effects on alertness and thinking, the risks it carries, and how its use fits a long-term health and longevity strategy that depends on good sleep.

Benefits - Risks - Protocol - Conclusion

This section lists expert discussions of modafinil’s uses, mechanisms and trade-offs, including its use alongside stimulant medications for attention-deficit/hyperactivity disorder (ADHD, a condition of persistent inattention, hyperactivity and impulsivity).

  • Adderall, Stimulants & Modafinil for ADHD: Short- & Long-Term Effects - Andrew Huberman

    A Stanford neuroscientist’s solo episode with a dedicated segment on modafinil and armodafinil (its longer-acting mirror-image form), comparing their mechanism, side effects, addiction potential and long-term use with amphetamine-type stimulants.

  • Preview – AMA #4: sleep, jet lag protocol, and more - Peter Attia

    A physician’s show notes laying out a modafinil-based jet-lag protocol (200 mg on waking after an overnight flight), with his view of its dose range, uncertain mechanism, safety and military use.

  • #113 - Modafinil: An All-Nighter In A Pill? - Matt Walker

    A sleep neuroscientist traces modafinil’s path from sleep-disorder treatment to military and workplace enhancer, and argues that it masks fatigue without replacing the restorative functions of sleep.

  • Modafinil & Your Brain - Alzheimer’s Drug Discovery Foundation

    A brain-health evidence summary noting gains on complex tasks in healthy people, mostly minor side effects, rare serious skin and psychiatric reactions, and no studies on preventing cognitive decline or dementia.

  • Modafinil: a review of neurochemical actions and effects on cognition - Minzenberg & Carter, 2008

    A comprehensive narrative review of modafinil’s effects on dopamine, norepinephrine, serotonin, glutamate, orexin (a wake-stabilizing brain peptide) and histamine, and on working memory and cognitive control in animals, healthy adults and psychiatric patients.

No dedicated modafinil content was found from Rhonda Patrick, Chris Kresser or Lifespan.io: their site searches return only passing mentions or unrelated pages. Life Extension’s site search could not be retrieved, and web searches found only passing mentions in Life Extension protocol pages, not an article on modafinil.

Grokipedia

Modafinil

A machine-written encyclopedia overview covering modafinil’s discovery, approved uses, dopamine-transporter mechanism, clinical trial results, off-label (unapproved) cognitive use and safety profile.

Examine

No Examine article on modafinil was found. Examine.com does not typically cover prescription medications.

ConsumerLab

No ConsumerLab article on modafinil was found. ConsumerLab does not typically cover prescription medications.

Systematic Reviews

These systematic reviews and meta-analyses (statistical pooling of several trials) cover modafinil’s effects on cognition, sleepiness and depression, and its adverse-event profile.

Mechanism of Action

Modafinil is a eugeroic (wakefulness-promoting drug) whose exact action is still debated.

  • Dopamine transporter blockade: In a positron emission tomography (PET, an imaging scan that tracks radioactive tracers) study, 200–400 mg occupied about half of striatal (deep-brain movement and reward region) dopamine transporters (DAT, the protein that clears dopamine from nerve junctions) and raised dopamine, including in reward regions (Volkow et al., 2009).
  • Other networks: It also raises norepinephrine, histamine, orexin and glutamate activity and lowers GABA (gamma-aminobutyric acid, the main calming neurotransmitter) signaling, preferentially in the cortex (Minzenberg & Carter, 2008; Battleday & Brem, 2015).
  • Competing view: The manufacturer long described it as unlike amphetamine: it does not increase dopamine release (Provigil product label, issued by manufacturer Cephalon/Teva), and stimulant-experienced volunteers did not rate it amphetamine-like (Jasinski, 2000). The imaging data instead show the transporter blockade typical of conventional stimulants.
  • Pharmacology: Its selectivity centers on the dopamine transporter; it does not directly activate dopamine receptors. Blood levels peak at 2–4 hours; the effective half-life (time for blood levels to halve) is about 15 hours, driven by the longer-lived R-enantiomer (mirror-image form). About 60% binds to blood proteins, and it spreads moderately into tissues (distribution volume 0.9 L/kg). About 90% is metabolized in the liver, mainly by amide hydrolysis (enzymatic splitting of the molecule) and partly by CYP3A4 (a major drug-clearing liver enzyme). It weakly induces CYP3A4 and inhibits CYP2C19 (an enzyme clearing drugs such as diazepam) (product label; Robertson & Hellriegel, 2003, Cephalon employees).

Historical Context & Evolution

Modafinil came from 1970s work at the French company Laboratoire L. Lafon on adrafinil, a wake-promoting compound whose active metabolite it is. It was first marketed in Europe in 1992 (European Medicines Agency) and approved in the United States in 1998 for narcolepsy (a brain disorder of overwhelming daytime sleepiness), later extended to obstructive sleep apnea (OSA, repeated airway collapse during sleep) and shift work disorder (sleepiness caused by night or rotating shifts) (product label; US Department of Justice).

Military research turned attention to healthy users: a US Army trial found that 200–400 mg maintained alertness after more than 41 hours awake about as well as 600 mg of caffeine (Wesensten et al., 2002), though in a Canadian defence trial users overestimated their own performance (Baranski & Pigeau, 1997).

In 2008 Cephalon agreed to a criminal plea and a $425 million payment to resolve allegations of off-label promotion (marketing for unapproved uses), including promoting Provigil as a non-stimulant for tiredness and fatigue (US Department of Justice). In 2009 imaging showed stimulant-like dopamine-transporter blockade, challenging the “non-stimulant” framing (Volkow et al., 2009). In 2010 European regulators recommended restricting use to narcolepsy, judging evidence in other sleep disorders insufficient against skin, psychiatric and cardiovascular risks (European Medicines Agency); the United States kept the broader indications (product label).

A 2015 review reported gains on complex tasks in healthy users (Battleday & Brem, 2015), while a later meta-analysis put the average effect at small (Kredlow et al., 2019); neither has closed the question.

Expected Benefits

High 🟩 🟩 🟩

Sustained wakefulness in sleep disorders and during sleep loss ⚠️ Conflicted

Modafinil lengthens objective wakefulness. Placebo-controlled trials, all Cephalon-funded, from the US narcolepsy study group (1998; 2000) and Czeisler’s Harvard group in shift work disorder (Czeisler et al., 2005), plus Wesensten’s US Army group after 41 hours awake (Wesensten et al., 2002), all found benefit. A 2026 meta-analysis whose co-authors include employees of Libbs, a Brazilian modafinil marketer, found no significant change in continuous Epworth Sleepiness Scale (ESS, a 0–24 self-rated sleepiness score) results in OSA (de Lima et al., 2026). Net: objective wakefulness improves consistently; self-rated sleepiness improves less reliably.

Magnitude: In narcolepsy, the Maintenance of Wakefulness Test (MWT, minutes a person stays awake in a dim room) rose 2.82 minutes more than with placebo; 95% confidence interval (CI, the range likely to contain the true value) 2.40–3.24 (Golicki et al., 2010). In OSA, ESS fell 2.2 points more (95% CI 1.5–2.9) and MWT rose 3 minutes more (95% CI 2.1–3.8) than with placebo, modafinil and armodafinil pooled (Chapman et al., 2016).

Small gains in cognitive performance in rested adults ⚠️ Conflicted

In adults who are not sleep-deprived, single 100–200 mg doses modestly improve attention, executive function and memory. Meta-analyses by Kredlow’s Boston University group (Kredlow et al., 2019) and Roberts’ Liverpool group (Roberts et al., 2020) pooled trials from independent labs, and Turner’s Cambridge trial found gains on memory and planning tests (Turner et al., 2003). Randall’s London trials found few effects in young and middle-aged volunteers (Randall et al., 2004; Randall et al., 2005). Net: a real but small average effect, clearest on complex tasks.

Magnitude: Hedges’ g (a standardized effect size; 0.2 is conventionally small) 0.10 greater than placebo (95% CI 0.05–0.15) across 19 trials (Kredlow et al., 2019); standardized mean difference (SMD, the difference in standard-deviation units) 0.12 across 14 studies (Roberts et al., 2020).

Medium 🟩 🟩

Less fatigue in chronic neurological and medical illness ⚠️ Conflicted

Modafinil has been tested against fatigue in multiple sclerosis (MS, an autoimmune disease of the brain and spinal cord), traumatic brain injury and cancer. A meta-analysis of seven controlled MS trials found less fatigue (Ghazanfar et al., 2024), and in 631 chemotherapy patients only those with severe fatigue benefited (Jean-Pierre et al., 2010). The largest MS trial (115 patients) found no difference from placebo (Stankoff et al., 2005), and an earlier meta-analysis confirmed benefit only after brain injury (Sheng et al., 2013). Net: modest relief, mainly in severe fatigue.

Magnitude: Modified Fatigue Impact Scale (MFIS, a 0–84 fatigue score) 4.42 points lower than placebo in MS (95% CI 0.84–8.01) (Ghazanfar et al., 2024).

Low 🟩

Add-on improvement in depression ⚠️ Conflicted

Added to standard depression treatment, modafinil or armodafinil modestly improved depression and remission (Goss et al., 2013; Nunez et al., 2020); pooling armodafinil, a different enantiomer, makes this indirect. The largest modafinil-only trial (311 patients, Cephalon-funded) missed significance on depression scales (Fava et al., 2005). Net: unproven for modafinil alone.

Magnitude: SMD −0.35 on depression scores (95% CI −0.61 to −0.10) and remission odds ratio (OR, relative odds of an outcome) 1.61 (95% CI 1.04–2.49) versus placebo, armodafinil trials included (Goss et al., 2013).

Adult attention-deficit symptoms ⚠️ Conflicted

Trials in children and adolescents reduced ADHD symptoms (Wang et al., 2017), but the largest adult trial (330 patients, Cephalon-sponsored) found no benefit at any dose (Arnold et al., 2014), as did an adult meta-analysis (Stuhec et al., 2019). Net: no demonstrated benefit in adults.

Magnitude: Adults: SMD 0.08 versus placebo (95% CI −0.18 to 0.34), no benefit (Stuhec et al., 2019); children: SMD −0.77 on home ratings (95% CI −1.11 to −0.44) (Wang et al., 2017).

Negative symptoms of schizophrenia ⭕️ Not Central to Health & Longevity

Added to antipsychotics (drugs for psychosis, a loss of contact with reality), pooled modafinil and armodafinil (a different enantiomer; indirect) slightly eased negative symptoms (apathy, withdrawal), losing significance without one acute-illness trial (Andrade et al., 2015); Cochrane rated evidence low quality (Ortiz-Orendain et al., 2019). It bears on psychiatric treatment.

Magnitude: SMD −0.26 versus placebo (95% CI −0.48 to −0.04), equal to 0.27 points on the negative-symptom subscale (Andrade et al., 2015).

Reduced stimulant use ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

Modafinil was tested for stimulant use disorder (compulsive cocaine or methamphetamine use). Seven cocaine trials reporting abstinence showed no overall gain, only a US subgroup benefit (Sangroula et al., 2017); methamphetamine trials found none (Elkrief et al., 2024). It bears on addiction treatment. Net: no reliable benefit.

Magnitude: Cocaine abstinence risk ratio (RR, how many times more often an outcome occurs) 1.26 versus placebo (95% CI 0.81–1.95), not significant (Sangroula et al., 2017).

Speculative 🟨

Protection of dopamine-producing neurons

In marmosets given MPTP (a toxin that destroys dopamine neurons), modafinil preserved movement and striatal dopamine (van Vliet et al., 2006). No human or lifespan data exist; the basis is animal work only.

Anti-inflammatory effects

A review of 14 experimental studies reports reduced inflammation via NF-κB (a master inflammation switch) and COX-2 (an inflammatory enzyme) inhibition (Amini et al., 2025). No human data exist; the basis is experimental only.

Benefit-Modifying Factors

  • Genetic polymorphisms: During sleep deprivation, carriers of the Val/Val form of COMT (catechol-O-methyltransferase, an enzyme that breaks down prefrontal dopamine) kept their performance and vigor on modafinil, while Met/Met carriers barely responded (Bodenmann et al., 2009).
  • Baseline biomarkers: Baseline sleepiness and fatigue scores predict benefit: effects are clear after sleep loss (Wesensten et al., 2002) and small in rested adults (Kredlow et al., 2019), and in chemotherapy only severe baseline fatigue responded (Jean-Pierre et al., 2010). No blood biomarker predicts response.
  • Sex: Modafinil’s pharmacokinetics (how the body absorbs and clears it) do not differ by sex (product label), and no consistent sex difference in benefit has been reported.
  • Pre-existing conditions: Benefit is best documented in narcolepsy, shift work disorder and OSA. In OSA it treats sleepiness only, not the airway obstruction, so continuous positive airway pressure (CPAP, mask-delivered air pressure that keeps the airway open) remains necessary (product label).
  • Age: Volunteers aged 50–67 showed limited cognitive gains (Randall et al., 2004). Older adults clear modafinil more slowly, so a given dose produces higher blood levels (product label).

Potential Risks & Side Effects

High 🟥 🟥 🟥

Headache ⚠️ Conflicted

Headache is the most common adverse event, dose-related and the leading reason for stopping in the Cephalon-sponsored registration trials (trials submitted for drug approval) (product label). Meta-analyses by de Lima’s group, which includes Libbs staff (de Lima et al., 2026), and Jung’s independent Yonsei group (Jung et al., 2026) confirm the excess. One narcolepsy trial found headache not significantly more frequent than with placebo (US narcolepsy group, 2000). Net: a consistent, mostly mild excess.

Magnitude: 34% with modafinil versus 23% with placebo in pooled trials (product label); RR 1.38 (95% CI 1.10–1.72) in OSA and shift work trials (de Lima et al., 2026).

Insomnia and shortened sleep ⚠️ Conflicted

With a roughly 15-hour half-life, modafinil can intrude on the next sleep period. Pooled registration trials and de Lima’s meta-analysis show more insomnia (product label; de Lima et al., 2026), and in Rattray’s Canberra crossover trial (each volunteer received drug and placebo) a single dose shortened that night’s sleep (Rattray et al., 2019). Nighttime sleep was unchanged in a narcolepsy trial (US narcolepsy group, 2000), and pre-shift dosing did not disturb daytime sleep (Czeisler et al., 2005). Net: sleep loss is common and depends on timing.

Magnitude: Insomnia 5% versus 1% with placebo (product label); RR 4.64 (95% CI 2.21–9.75) (de Lima et al., 2026); 5.5 versus 7.5 hours of sleep after a single dose versus placebo (Rattray et al., 2019).

Nausea, digestive upset and reduced appetite

Nausea, diarrhea, indigestion, constipation and loss of appetite occur more often than with placebo in the registration trials (product label), confirmed by meta-analyses from de Lima’s and Jung’s groups (de Lima et al., 2026; Jung et al., 2026). Effects are usually mild; appetite loss may appeal to some users but can undercut protein and energy intake.

Magnitude: Nausea 11% versus 3%, constipation 2% versus 1% and loss of appetite 4% versus 1% with placebo (product label); nausea RR 2.57 (95% CI 1.33–4.97) (de Lima et al., 2026).

Anxiety and nervousness

Modafinil’s catecholamine (adrenaline-family messenger) effects can produce anxiety, nervousness and jitteriness, with anxiety dose-related in the Cephalon-sponsored registration trials (product label). Meta-analyses by de Lima’s and Jung’s groups confirm the excess across sleep disorders and depression (de Lima et al., 2026; Jung et al., 2026).

Magnitude: Anxiety 5% versus 1% and nervousness 7% versus 3% with placebo (product label); anxiety or nervousness RR 3.08 (95% CI 1.49–6.39) (de Lima et al., 2026).

Medium 🟥 🟥

Raised blood pressure, heart rate and cardiovascular symptoms ⚠️ Conflicted

Modafinil activates the sympathetic (fight-or-flight) nervous system: in Taneja’s Vanderbilt crossover trial of 12 volunteers, 400 mg raised heart rate, blood pressure and urinary adrenaline (Taneja et al., 2005). Pooled three-month registration trials showed no meaningful change in average blood pressure, yet more users needed new or increased blood-pressure medication, and chest pain and palpitations were more frequent (product label). Net: small average rises, with clinically relevant increases in a minority.

Magnitude: Heart rate 9.2 beats per minute higher (95% CI 4.7–13.6), systolic pressure 7.3 mmHg higher (95% CI 0.2–14.4) and diastolic 5.3 mmHg higher (95% CI 1.4–9.1) than placebo after 400 mg (Taneja et al., 2005); new or increased blood-pressure medication use 2.4% versus 0.7%, chest pain 3% versus 1% and palpitations 2% versus 1% with placebo (product label).

Serious rash, hypersensitivity and blood reactions

Modafinil can trigger Stevens-Johnson syndrome (SJS, a life-threatening blistering skin reaction) and toxic epidermal necrolysis (TEN, its more extensive form), and DRESS (a drug reaction with raised allergy-type white cells and multi-organ involvement), mostly 1–5 weeks after starting; angioedema (deep tissue swelling), anaphylaxis (severe whole-body allergy) and agranulocytosis (loss of infection-fighting white cells) are also reported. Evidence comes from the manufacturer’s pediatric trials and postmarketing reports (product label), plus adult case reports (Prince et al., 2018; Kasitinon et al., 2022). No known factor predicts who is affected.

Magnitude: Rash leading to discontinuation in 0.8% (13 of 1,585) of children versus none of 380 on placebo; adult SJS and TEN reports exceed the background of 1–2 cases per million person-years (postmarketing reports, no control group) (product label).

Overconfidence and masked sleep debt

In Baranski’s Canadian defence trial during 64 hours without sleep, modafinil improved performance but led users to overestimate their accuracy, unlike amphetamine; the dose (300 mg) exceeded the usual 200 mg (Baranski & Pigeau, 1997). Shift workers on modafinil stayed excessively sleepy at night despite improvement (Czeisler et al., 2005). Restored alertness can hide persisting impairment from lost sleep.

Magnitude: Overestimation of one’s own cognitive performance during sleep deprivation, most marked 2–4 hours after dosing; the literature reports no outcome figure (Baranski & Pigeau, 1997).

Liver enzyme rises

Mean gamma-glutamyl transferase (GGT, a liver enzyme) and alkaline phosphatase (ALP, a liver and bone enzyme) rose with modafinil but not placebo in the Cephalon registration trials, and shifts grew over time, though few values left the normal range (product label). A pooled analysis of the same six trials, sponsored by Cephalon and co-authored by its employees, found clinically significant laboratory abnormalities in under 1% of users (Roth et al., 2007). Hepatitis has occurred within multi-organ hypersensitivity reactions (product label).

Magnitude: Abnormal liver function 2% versus 1% with placebo (product label).

Nose and throat inflammation, back pain, dry mouth and tingling

Rhinitis (inflamed, runny or blocked nose), pharyngitis (sore, inflamed throat), back pain, dry mouth and paresthesia (tingling or pins-and-needles sensations) are among the label’s listed adverse reactions, each slightly more frequent than with placebo in the pooled Cephalon registration trials (product label). A pooled safety analysis of the same trials judged modafinil well tolerated overall (Roth et al., 2007). The excess over placebo is small.

Magnitude: Rhinitis 7% versus 6%, pharyngitis 4% versus 2%, back pain 6% versus 5%, dry mouth 4% versus 2% and paresthesia 2% versus 0% with placebo (product label).

Low mood and dizziness

Depression and dizziness were each slightly more frequent with modafinil than with placebo in the pooled Cephalon registration trials, and dizziness was among the leading reasons for stopping (product label). A pooled safety analysis of the same six trials, sponsored by Cephalon, found adverse events similar across narcolepsy, sleep apnea and shift work patients (Roth et al., 2007). Both signals come from one sponsor’s trials, and the excess over placebo is small.

Magnitude: Depression 2% versus 1% and dizziness 5% versus 4% with placebo (product label).

Low 🟥

Birth defects after exposure in pregnancy ⚠️ Conflicted

Danish registries linked first-trimester exposure to malformations (Damkier & Broe, 2020), as did Teva’s uncontrolled registry (Kaplan et al., 2025). Larger French cohorts found no significant increase versus unexposed pregnancies (Kaplan et al., 2026, Teva staff; Kanoun et al., 2026); Kanoun’s rose versus methylphenidate. Net: a modest risk is unconfirmed.

Magnitude: Major malformations 12% (6 of 49) versus 3.9% in unexposed pregnancies, adjusted odds ratio (aOR, odds after accounting for other factors) 2.7 (95% CI 1.1–6.9) (Damkier & Broe, 2020); 4.2% versus 3.3%, adjusted RR 1.32 (95% CI 0.81–2.15) (Kaplan et al., 2026).

Psychiatric reactions

Mania (abnormally elevated mood and energy), delusions, hallucinations, suicidal ideation and aggression appear in postmarketing reports, many in people with a psychiatric history (product label). A review of 24 cases found psychosis even at usual doses; most improved with treatment (Sato et al., 2026).

Magnitude: Not quantified in available studies. Serious psychiatric reactions are known only from postmarketing and case reports, which have no comparison group.

Misuse and dependence ⚠️ Conflicted

Stimulant-experienced volunteers recognized and liked modafinil, though not as amphetamine-like (Jasinski, 2000); case reports describe dependence (Krishnan & Chary, 2015). No withdrawal followed nine weeks of use (US narcolepsy group, 2000). Net: low but real misuse potential.

Magnitude: Not quantified in available studies. Dependence is documented only in case reports, and no controlled trial has measured its incidence.

Speculative 🟨

Unknown effects of years of use in healthy brains

No trial has followed healthy users for years. Dopamine-transporter blockade like that of conventional stimulants (Volkow et al., 2009) and self-administration by monkeys (product label) suggest possible adaptation; the basis is mechanistic only.

Risk-Modifying Factors

  • Genetic polymorphisms: In people lacking CYP2D6 activity (an antidepressant-clearing enzyme; 7–10% of white people), modafinil can raise levels of tricyclic antidepressants (an older antidepressant class) (product label). COMT genotype altered modafinil’s effects on recovery sleep (Bodenmann & Landolt, 2010). No genetic rash predictor is known.
  • Baseline biomarkers: Elevated baseline blood pressure or heart rate leaves less margin for modafinil’s increases (Taneja et al., 2005). Severe liver impairment cuts clearance by about 60% and doubles blood levels during regular use (product label).
  • Sex: Women using hormonal contraception face reduced contraceptive reliability during use and for one month after (product label); women who may conceive carry the unresolved malformation signal (Damkier & Broe, 2020).
  • Pre-existing conditions: History of psychosis, mania or depression, left ventricular hypertrophy (thickened heart muscle), mitral valve prolapse (a floppy heart valve) with prior stimulant symptoms, recent heart attack, or stimulant misuse raises risk (product label).
  • Age: In patients averaging 82 years, blood levels were about twice those of younger adults, so lower doses are advised; experience above age 65 is limited (product label).

Key Interactions & Contraindications

Prescription drugs:

  • Hormonal contraceptives (oral ethinyl estradiol, patches, rings): Modafinil lowered ethinyl estradiol exposure by 18% through CYP3A4 induction, risking contraceptive failure; the label recommends backup or non-hormonal contraception during use and for one month after stopping (Robertson et al., 2002, Cephalon employees; product label).
  • CYP3A4 substrates (triazolam, midazolam, cyclosporine): Triazolam exposure fell 59% (Robertson et al., 2002), midazolam’s about a third (Rowland et al., 2018), and one transplant patient’s cyclosporine level 50%, risking loss of effect or rejection; the label recommends dose adjustment and cyclosporine monitoring (product label).
  • CYP2C19 substrates (diazepam, phenytoin, propranolol): Inhibited clearance can raise levels, causing excess sedation, phenytoin toxicity or low blood pressure; the label notes dose adjustment may be necessary (product label).
  • Tricyclics and selective serotonin reuptake inhibitors (SSRIs, common antidepressants) in CYP2D6 poor metabolizers (desipramine, clomipramine, fluoxetine): Levels may rise, causing sedation or heart-rhythm effects; a human study found no clomipramine interaction, but one patient’s levels rose. The label advises considering dose adjustment (product label).
  • Warfarin: A single-dose study found no change in warfarin levels, but an interaction with ongoing use is not excluded and could shift clotting control and bleeding risk; the label suggests more frequent INR (international normalized ratio, a clotting-time test) checks (product label).
  • Monoamine oxidase (MAO) inhibitors (antidepressants that block catecholamine breakdown; phenelzine, tranylcypromine, selegiline): Combined use may add to blood pressure and stimulation; the label urges care, and blood pressure checks limit the risk (product label).
  • Other stimulants (methylphenidate, dextroamphetamine): Human studies found no change in either drug’s blood levels (product label); additive heart rate, blood pressure and insomnia remain likely (theoretical), which lower doses of each limit.
  • Strong CYP3A4 inducers or inhibitors (carbamazepine, rifampin, phenobarbital; ketoconazole, erythromycin): These could lower or raise modafinil levels, altering effect or side effects (product label); a Cephalon review rates major changes unlikely (Robertson & Hellriegel, 2003). Watching for changed effect when starting or stopping limits this.

Over-the-counter medications:

  • Proton-pump inhibitors (acid-reducing drugs; omeprazole, esomeprazole): In an independent human study, modafinil 200 mg daily raised omeprazole exposure 1.9-fold through CYP2C19 inhibition (Rowland et al., 2018), which may add to acid-suppressant side effects; using the lowest effective dose limits this.
  • Decongestants (pseudoephedrine, phenylephrine): Both raise blood pressure and heart rate, adding to modafinil’s effect (theoretical); avoiding the combination or checking blood pressure limits the risk.
  • Sedating antihistamines (diphenhydramine, doxylamine): These oppose modafinil’s alertness and can mask late-dose insomnia (theoretical); earlier modafinil dosing removes the insomnia they are often taken for.

Supplements and dietary stimulants:

  • Caffeine: In a human study, armodafinil did not change caffeine metabolism (product label); additive jitteriness, anxiety, heart rate and insomnia remain likely (theoretical), so caffeine intake is usually reduced.
  • Stimulant supplements (synephrine/bitter orange, yohimbine, theacrine): Additive blood pressure, heart rate and anxiety effects (theoretical); avoiding stacking limits cardiovascular strain.
  • St John’s wort: As a CYP3A4 inducer, it may lower modafinil levels and further weaken hormonal contraception (theoretical); avoiding the combination is the usual approach.

Other interventions:

  • CPAP for sleep apnea: Modafinil treats sleepiness, not airway obstruction, so using it in place of CPAP leaves the airway obstruction untreated; the label calls for continued CPAP use during treatment (product label).
  • Alcohol: Combined use has not been studied, so its effect on alertness, impairment or side effects is unknown; the label advises avoiding alcohol while taking modafinil (product label).
  • Sleep restriction and night work: Modafinil improves but does not normalize alertness in shift workers, so driving after night shifts still carries risk (Czeisler et al., 2005); the label advises avoiding driving and other hazardous tasks while sleepiness persists (product label).

Populations who should avoid Modafinil:

  • Known hypersensitivity to modafinil or armodafinil (contraindicated) (product label)
  • Prior serious rash, angioedema or multi-organ hypersensitivity with modafinil or armodafinil (product label)
  • Left ventricular hypertrophy, or mitral valve prolapse with prior stimulant-related chest pain, ischemic (reduced-blood-flow) ECG (electrocardiogram, heart-rhythm tracing) changes or arrhythmia (irregular heart rhythm) (product label)
  • Uncontrolled high blood pressure or irregular heartbeat (European Medicines Agency)
  • Pregnancy or planned pregnancy (product label; Damkier & Broe, 2020)
  • Children and adolescents under 17 years, owing to serious rash risk (product label)
  • Active psychosis or mania, given postmarketing psychiatric reactions; the label urges caution with a history of psychosis or mania and advises considering discontinuation if psychiatric symptoms develop (product label)

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Morning-only dosing: Taking modafinil on waking and not after early afternoon limits insomnia and shortened sleep, given its roughly 15-hour half-life (product label).
  • Lowest effective dose: Starting at 100 mg, the lowest tablet strength, limits dose-related headache and anxiety; trials show no consistent added benefit above 200 mg (product label).
  • Stop at the first rash: Stopping at the first sign of rash unless clearly unrelated, and seeking care for fever, blisters or facial swelling, limits progression of SJS, TEN, DRESS or angioedema (product label).
  • Blood pressure checks: Measuring blood pressure and heart rate before starting and after 2–4 weeks catches stimulant-related rises; hypertension starts at 130/80 mmHg in the 2025 guideline of cardiology societies whose members earn revenue treating it (Jones et al., 2025).
  • Contraception and pregnancy: Non-hormonal or backup contraception during use and for one month after, and stopping before trying to conceive, prevents contraceptive failure and fetal exposure (product label).
  • Protect sleep opportunity: Keeping a full sleep schedule rather than using modafinil to replace sleep limits overconfidence and accumulating sleep debt (Baranski & Pigeau, 1997).
  • Cut back caffeine: Reducing caffeine and avoiding stimulant supplements on modafinil days limits additive anxiety, insomnia and heart-rate rises.
  • Intermittent use: Limiting use to specific demanding days, such as travel or deadlines, reduces cumulative exposure, tolerance concerns and misuse risk.
  • Psychiatric watch: Stopping and seeking assessment if agitation, elation, paranoia, hallucinations or suicidal thoughts appear prevents escalation of psychiatric reactions (product label).

Therapeutic Protocol

Timing, cycling and titration (stepwise dose adjustment) steps below reflect common practice unless cited.

  • Label regimen for sleep disorders: 200 mg once each morning for narcolepsy or OSA, or 200 mg about one hour before a night shift; 400 mg adds no consistent benefit (product label).
  • As-needed travel protocol: Peter Attia describes 200 mg on waking after an overnight flight to stay awake on destination time (Attia, Ask Me Anything #4 show notes).
  • Cognitive-use doses in trials: Single 100 or 200 mg doses in rested adults performed alike (Kredlow et al., 2019); for approved uses, the Alzheimer’s Drug Discovery Foundation (no fee-earning members) lists 100–200 mg each morning (Cognitive Vitality summary).
  • Sleep-loss doses in research: 200 or 400 mg after 41.5 hours awake matched 600 mg caffeine in an Army trial (Wesensten et al., 2002); a partly Cephalon-funded Harvard study gave 400 mg daily in three doses (Grady et al., 2010).
  • Competing approaches: Daily dosing is standard in sleep disorders, while health-focused users favor occasional use; caffeine is a cheaper equivalent during acute sleep loss (Wesensten et al., 2002), and armodafinil, the longer-acting R-enantiomer, is a related option.
  • Best time of day: Morning, on waking; blood levels peak 2–4 hours later, and food delays the peak by about one hour without reducing absorption (product label).
  • Half-life: About 12–15 hours (Robertson & Hellriegel, 2003), with steady state after 2–4 days of daily use (product label).
  • Single versus split dose: The label uses one morning dose; split dosing (morning and late morning) extends coverage but raises late-day exposure and insomnia risk.
  • Genetic polymorphisms: COMT Val/Val carriers responded more strongly during sleep loss (Bodenmann et al., 2009), but no genotype-based dosing exists; for CYP2D6 poor metabolizers taking antidepressants, the label notes dose adjustment may be needed (product label).
  • Sex: Doses do not differ by sex, as pharmacokinetics are similar; for women on hormonal contraception, the label recommends backup contraception (product label).
  • Age: Lower doses and closer monitoring are advised in older adults because clearance falls with age; 100 mg is the lowest tablet strength (product label).
  • Baseline biomarkers: Higher baseline blood pressure favors the lowest dose; in rested adults without sleep loss, gains are small (Kredlow et al., 2019).
  • Pre-existing conditions: Severe liver impairment calls for half the usual dose (product label); people with OSA continue CPAP.

Discontinuation & Cycling

  • Short-term versus long-term use: Health-focused use is typically intermittent or short-term; in sleep disorders, use is long-term, with efficacy maintained over 40 weeks of open-label (unblinded) treatment (US narcolepsy group, 1998).
  • Withdrawal effects: No withdrawal symptoms appeared over 14 days after nine weeks of use, though sleepiness returned to baseline in narcolepsy patients (US narcolepsy group, 2000).
  • Tapering: No taper is required; trial participants stopped abruptly (US narcolepsy group, 2000). Some daily users step down from 200 to 100 mg for a few days.
  • Cycling for efficacy: Tolerance did not develop over 40 weeks (US narcolepsy group, 1998), so cycling is not needed to keep the effect; drug-free days are used to limit exposure and misuse.
  • After stopping: The contraceptive interaction persists for one month after the last dose (product label).

Sourcing and Quality

  • Prescription-only controlled substance: In the United States, modafinil is a Schedule IV controlled substance (a category for drugs with recognized but limited abuse potential) dispensed by prescription (product label).
  • Brand and generic options: Provigil (Cephalon/Teva) and numerous generic 100 mg and 200 mg tablets, including from Aurobindo, Apotex, Zydus and Alembic, are listed on DailyMed (DailyMed modafinil labels).
  • Online products: Tablets sold online without prescription, often under the Indian brand names Modalert or Modvigil, bypass pharmacy supply chains, so identity, dose and purity cannot be verified by the buyer.
  • What to look for: Pharmacy-dispensed tablets with a National Drug Code on the label, consistent imprint markings and an accompanying medication guide.
  • Formulation: Only immediate-release tablets exist; armodafinil, the single-enantiomer form, is a separate product with a longer effect.
  • Third-party testing: Supplement-testing programs do not cover prescription drugs, so pharmacy dispensing, not independent testing, is the quality safeguard.

Practical Considerations

  • Time to effect: Alertness effects begin within hours, as blood levels peak 2–4 hours after a dose (product label); no build-up period is needed for wakefulness.
  • Common pitfalls: Dosing late in the day, using modafinil instead of sleep, adding high caffeine intake, overlooking the contraceptive interaction, and dismissing an early rash.
  • Regulatory status: Approved in the United States for sleepiness in narcolepsy, OSA and shift work disorder; Schedule IV; cognitive enhancement is off-label (product label). In the European Union, approval covers narcolepsy only (European Medicines Agency).
  • Access: Generic tablets are inexpensive, but off-label prescribing for healthy adults depends on individual physicians.

Interaction with Foundational Habits

  • Sleep: Direct and potentially blunting. A single dose cut that night’s sleep by about two hours (Rattray et al., 2019); unlike caffeine, modafinil did not reduce deep slow-wave sleep after sleep deprivation (Bodenmann & Landolt, 2010). Early-morning dosing and fixed sleep times limit the impact.
  • Nutrition: Indirect. Modafinil reduces appetite in some users, which can undercut protein intake (product label). Food delays the peak by about one hour without reducing absorption. Grapefruit, a CYP3A4 inhibitor, may modestly raise levels (theoretical). No nutrient depletion is known.
  • Exercise: None on endurance, potentiating on heart rate. After mental fatigue, modafinil improved executive function but not endurance, and heart rate during submaximal (below-peak effort) exercise was higher (134 versus 119 beats per minute) (Rattray et al., 2019). Heart-rate training zones (intensity bands set by heart rate) may read high on dosing days.
  • Stress management: Potentiating the stress system. Modafinil raised plasma and urinary norepinephrine and urinary adrenaline (Taneja et al., 2005), but unlike MDMA (ecstasy) it did not markedly raise cortisol at 600 mg (Dolder et al., 2018). Anxiety is dose-related, so lower doses limit it in stress-prone users.

Monitoring Protocol & Defining Success

Baseline testing before the first dose establishes cardiovascular status, pregnancy status and personal reference values. It includes blood pressure and resting heart rate measured on several mornings, a pregnancy test for women who could conceive, a liver panel with gamma-glutamyl transferase (GGT, a liver enzyme) and alkaline phosphatase (ALP, a liver and bone enzyme), one to two weeks of sleep tracking, and an Epworth sleepiness score.

Ongoing monitoring follows this cadence: blood pressure and heart rate at 2 weeks and 4 weeks, then every 3–6 months; the liver panel at 3 months, then every 6–12 months during regular use; sleep duration and the Epworth score weekly for the first month, then monthly. Success means the targeted gain in alertness or focus on use days, without lost sleep, rising blood pressure or new psychiatric symptoms.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Blood pressure Below 120/80 mmHg, the “normal” category of the 2025 AHA/ACC guideline Safety check: modafinil can raise blood pressure Seated, rested, average of two or more morning readings. Conventional reference range: 90/60 to below 120/80 mmHg (standard reference range); hypertension is diagnosed at 130/80 mmHg or above. AHA/ACC: American Heart Association/American College of Cardiology, whose clinician members earn revenue from diagnosing and treating hypertension (Jones et al., 2025)
Resting heart rate 60–100 beats per minute (standard reference range) Safety check: modafinil can raise heart rate Measured on waking or after five minutes seated; compare with own baseline
GGT Men 8–61 U/L, women 5–36 U/L (standard reference range) Safety check: GGT rose in registration trials Gamma-glutamyl transferase, a liver enzyme; U/L: units per liter; ranges vary by laboratory; alcohol raises GGT; pair with ALP and ALT (alanine aminotransferase, a liver-injury enzyme)
ALP 40–129 U/L (standard reference range) Safety check: ALP rose in registration trials Alkaline phosphatase, a liver and bone enzyme; ranges vary by laboratory; no fasting required
Pregnancy test (hCG) Negative (standard reference range) Safety check: possible birth-defect risk hCG: human chorionic gonadotropin, the pregnancy hormone; repeat if contraception lapses
Sleep duration No established target; track change from the pre-modafinil baseline Marker modafinil is expected to change (can shorten sleep) Wearable or sleep diary; compare use days with non-use days
Epworth Sleepiness Scale No established target; track change from own baseline Marker modafinil is expected to change (daytime sleepiness) Self-rated 0–24 questionnaire; complete at the same time of day

Qualitative markers:

  • Daytime alertness and focus on demanding tasks
  • Ease of falling asleep and sleep quality
  • Mood, anxiety and irritability
  • Appetite and food intake
  • New skin rash, fever or swelling
  • Urges to raise the dose or use it more often

Emerging Research

  • Cold stress and sleep loss: A US Army trial (NCT07830056) tests modafinil in 33 rested and sleep-deprived volunteers under cold exposure, measuring vigilance, executive tasks and grip strength (Phase 4, completion December 2026). A positive result would extend the sleep-loss benefit to combined stressors; a null result would narrow it.
  • Post-stroke fatigue (MODEX): A Canadian trial (NCT06354985) randomizes 212 stroke survivors to modafinil 200 mg or placebo, both with home exercise, for 8 weeks; primary outcome is fatigue severity (Phase 3, not yet recruiting, completion September 2027). A positive result would strengthen the fatigue benefit; a null result would weaken it.
  • Fatigue in inflammatory bowel disease (MODIFI-IBD): A Dutch trial (NCT07582458) tests modafinil against placebo in 60 adults with inactive bowel disease and severe fatigue (Phase 2/3, completion June 2027). A positive result would broaden the fatigue benefit; a null result would confine it to neurological illness.
  • Single-dose cognition in healthy adults: A University of Minnesota trial (NCT07231497) gives one dose to 103 people without psychosis, measuring processing speed, memory, reasoning and brain-wave activity (completion 2030). A positive result would support the cognition benefit; a null result would reinforce its small size.
  • Pregnancy safety: Danish data (Damkier & Broe, 2020) and French cohorts (Kanoun et al., 2026) disagree; pooled multinational analyses could confirm or retire the malformation signal.
  • Long-term brain effects: Imaging shows dopamine-transporter blockade (Volkow et al., 2009), yet no study has followed healthy users for years; such data could reveal harms or reassure.
  • Next-generation analogs: A modafinil analog improved motivation and learning in aged rats (Gyertyán et al., 2021), pointing to compounds aimed at age-related cognitive decline.

Conclusion

Modafinil is a prescription wakefulness drug that blocks the brain’s recycling of dopamine and keeps people alert for many hours after a single morning dose. Its strongest evidence lies in keeping people awake: it reliably improves alertness in sleep disorders and during sleep loss, though people still feel sleepier than when well rested. For rested, healthy adults, the gain in thinking is real but small, showing up mostly on demanding tasks. Effects on fatigue in chronic illness are modest and inconsistent, and add-on use for depression or attention problems in adults rests on mixed or indirect evidence. No study links it to longer life or slower aging.

The costs are concrete. Headache, nausea, anxiety and lost sleep are common, and lost sleep matters most for anyone whose longevity strategy rests on sleep. Blood pressure and heart rate rise in some users, rare skin reactions can be life-threatening, psychiatric reactions and misuse occur, a possible birth-defect signal remains unresolved, and it weakens hormonal contraception. Users may also feel sharper than they are when short of sleep.

Much of the founding evidence comes from trials, registries and drug-handling studies funded or written by the manufacturers, and one recent analysis combining several trials included authors from a company that sells it. Independent work broadly confirms the wakefulness effect and the common side effects, while long-term effects of years of use in healthy people remain unknown.

Top - Benefits - Risks - Protocol